As of Thursday close, Novavax Inc.’s (NASDAQ:NVAX) stock was up $0.82, moving up 1.34 percent to $61.93. The average number of shares traded per day over the past five days has been 3,905,320 shares. 4 times new highs have been achieved over the past 5 days, with a $4.82 gain in that time frame. In the last twenty days, the average volume was 7,837,420, while in the previous 50 days, it was 7,569,606.
Since last month, NVAX stock retreated -2.53%. Shares of the company fell to $47.68 on 07/15/22, the lowest level in the past month. A 52-week high of $277.80 was reached on 01/03/22 after having rallying from a 52-week low of $34.88. Since the beginning of this year, NVAX’s stock price has dropped by -56.71% or -$81.14, and marked a new high 1 time. However, the stock has declined by -77.71% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Novavax Inc. (NVAX) last reported insider trading activity 127 days ago on Mar 31. YOUNG JAMES F, the Director of the company, disposed of 12,500 shares for $73.58 on Mar 31. It resulted in a $919,765 divestment by the insider. Herrmann John A III sold 5,000 shares at an average price of $140.91 on Jan 03. The insider now owns 3,845 shares following the transaction. On Dec 31, Director YOUNG JAMES F sold 3,750 shares at $144.16 apiece. The transaction was valued at $540,601.
The stock’s beta is 1.56. Besides these, the trailing price-to-sales (P/S) ratio of 3.57, the price-to-book (PB) ratio of 72.86.
In the three months ended March 30, Novavax Inc.’s quick ratio stood at 1.00, while its current ratio was 1.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 98.90% percent. In the year ended March 30, operating margins totaled -90.40%. Based on annual data, NVAX earned $2.83 billion in gross profit and brought in $1.15 billion in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NVAX’s revenue rose 36.47% to $222.2 million during the quarter, while net income inched up to $703.97 million. While analysts expected Novavax Inc. to report $2.69 quarterly earnings, the actual figure was $2.56 per share, beating the consensus estimate by -4.80%. During the quarter, the company generated $216.06 million in EBITDA. The liabilities of Novavax Inc. were 2.77 billion at the end of its most recent quarter ended March 30, and its total debt was $538.57 million. The value of shareholders’ equity is $78.14 million.
This quick technical analysis looks at Novavax Inc.’s (NVAX) price momentum. With a historical volatility rate of 66.52%, the RSI 9-day stood at 60.12% on 04 August.
With respect to its five-day moving average, the current Novavax Inc. price is up by +8.44% percent or $4.82. At present, NVAX shares trade -15.33% below its 20-day simple moving average and -20.37% percent below its 100-day simple moving average. However, the stock is currently trading approximately +15.93% above its SMA50 and -61.76% below its SMA200.
Stochastic coefficient K was 69.18% and Stochastic coefficient D was 50.67%, while ATR was 5.26. Given the Stochastic reading of 80.57% for the 14-day period, the RSI (14) reading has been calculated as 56.43%. As of today, the MACD Oscillator reading stands at 3.00, while the 14-day reading stands at 3.18.
BofA Securities launched its rating on Novavax Inc. (NASDAQ: NVAX) to an Underperform in a note to investors on May 20, 2022. Novavax Inc. (NVAX) has been rated Overweight by analysts. According to 0 brokerage firms, NVAX is a sell, and 1 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Novavax Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $160.50, the current consensus forecast for the stock is $35.00 – $207.00. Based on these forecasts, analysts predict Novavax Inc. (NVAX) will achieve an average price target of $147.50.